Gastroenterology Research

The division has a number of basic and clinical research projects in progress. The factors which regulate fluid and electrolyte absorption in both the small intestine and colon are active interests. Clinical research interests involve studies examining the etiology and therapy of diarrhea, gastrointestinal motility including small bowel motility, and, ultrasound techniques in chronic liver disease. Also, investigational drug studies with inflammatory bowel disease, peptic ulcer disease and gastroesophageal influx are in progress.

__________________________________________________________________________________________________

Do you have chronic hepatitis C (HCV)? Have you had a liver biopsy that showed no evidence of cirrhosis or hepatocellular carcinoma?  You may qualify to participate in a clinical trial.

A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects

_____________________________________________________________________________________

Do you have Irritable Bowel Syndrome with Diarrhea? Do you have recurrent abdominal pain or discomfort at least 3 days a month for the last 3 months?  You may qualify to participate in a clinical trial.

A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550mg TID in Subjects with Irritable Bowel Syndrome with Diarrhea (IBS-D)

_____________________________________________________________________________________

Do you have Ulcerative Colitis? Have you been diagnosed with UC for at least six months?  You may qualify to participate in a clinical trial with an investigational new drug.

“Phase 2 Assessment of the Relationship between Serotonin and Efficacy in Ulcerative Colitis: A Multi-Center Randomized, Double Blind, Placebo-Controlled, Pilot Study to Evaluate Safety and Preliminary  Efficacy of Orally Administered LX1606 in Subjects with Acute, Mild to Moderate Ulcerative Colitis”

_____________________________________________________________________________________

Do you have chronic hepatitis C (HCV)?  You may qualify to participate in a clinical trial.

An Open-Label, Phase 4 Study of Telaprevir, Peginterferon Alfa-2a (Pegasys®), and Ribavirin (Copegus®) in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C Who Have Not Achieved a Sustained Viral Response With a Prior Course of Interferon-Based Therapy

_____________________________________________________________________________________

University of Texas Health Science Center at Houston
Department of Gastroenterology, Hepatology & Nutrition
6431 Fannin
Houston, TX 77030

GI.Research@uth.tmc.edu
713-500-6669